Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Rossari Biotech Ltd ( (IN:ROSSARI) ) has shared an announcement.
Rossari Biotech reported a solid set of numbers for the quarter ended 31 December 2025, with consolidated revenue from operations rising 13% year-on-year to Rs 581.7 crore, driven by broader demand across its specialty chemicals portfolio. Quarterly EBITDA grew 6% to Rs 68.9 crore and profit after tax increased 3% to Rs 32.8 crore, though EBITDA margins softened to 11.8% from 12.6%, indicating some pressure on profitability despite the topline growth. For the nine months of FY26, revenue climbed 14% to Rs 1,711.5 crore and EBITDA was up 7% to Rs 208.7 crore, while PAT edged up 1% to Rs 103.2 crore, suggesting that Rossari is sustaining growth momentum but facing margin compression, a key point for investors tracking its competitive positioning and operating efficiency in the specialty chemicals space.
More about Rossari Biotech Ltd
Rossari Biotech Limited is a specialty chemicals manufacturer based in Mumbai, providing intelligent and sustainable solutions to customers across multiple industries. The company focuses on value-added formulations and customized chemistries that support diverse industrial applications while emphasizing environmentally conscious products.
Average Trading Volume: 1,562
Technical Sentiment Signal: Sell
Current Market Cap: 29.61B INR
Learn more about ROSSARI stock on TipRanks’ Stock Analysis page.